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The aim of our study was to examine the involvement of renin-angiotensin system (RAS) in estrogen-induced lactotropes
proliferation and vascular endothelial growth factor (VEGF) expression in rat pituitary. The study was performed on Fisher 344
rats underwent 8-day treatment with diethylstilboestrol (DES). The proliferation index (PCNA) and VEGF expression in pituitary
sections were estimated using immunohistochemical methods. Treatment with DES increased the number of PCNA-positive cells,
VEGF-positive cells, and VEGF-positive blood vessels in pituitary. Stimulatory eﬀe c to fe s t r o g e no nc e l lp r o l i f e r a t i o na n dV E G F
expression in blood vessels was attenuated by losartan, PD123319, and captopril. VEGF immunoreactivity in pituitary cells of
DES-treated rats was decreased by AT1 antagonist and not changed by AT2 blocker and ACE inhibitor. Our ﬁndings suggest the
involvement of RAS in DES-induced cell proliferation and VEGF expression in pituitary. Both the AT1 and AT2 receptors appear
to mediate the estrogen-dependent mitogenic and proangiogenic eﬀects in rat pituitary.
1.Introduction
Estrogens are well known to stimulate, both directly and
indirectly, the cellular proliferation in anterior pituitary,
and their growth-promoting eﬀects are largely conﬁned to
the lactotropes [1–3]. Pituitary lactotropes hyperplasia has
been observed in physiological states of estrogen excess,
during estrus in several species, and in human pregnancy
[4]. Heaney et al. have revealed the cyclic expression of the
pituitary tumor transforming gene (pttg), basic ﬁbroblast
growthfactor(bFGF),andvascularendothelialgrowthfactor
(VEGF) during the rat estrus cycle, with maximal expression
occurringwithpeakserumestradiol(E2),increasedpituitary
proliferation and angiogenesis [5]. The functional role of
estrogen receptor (ERα) in cell proliferation, prolactin (PRL)
secretion, and expression of some growth factors, including
the above-mentioned ones, in pituitary prolactinomas was
documented as well [6]. E2 has been found to induce the
transforming growth factor-beta 3 (TGF-β3) secretion from
lactotropes. TGF-β3 stimulated, in turn, the folliculostellate
(FS)cellstoreleasebothVEGFandbFGF,thepotentmitogen
for prolactin- (PRL-) secreting cells [7]. E2 augmented
also a level of the key potent proangiogenic cytokine,
VEGF, in prolactinoma tumor cell preparations [8]. In vivo,
chronic treatment with estrogens resulted in the increased
VEGF production and VEGF receptor expression in anterior
pituitary of rats [9]. Moreover, tumor formation in estrogen-
induced prolactinoma was shown to be associated with the
development of the direct arterial blood supply leading
the anterior pituitary cells to escape from hypothalamic2 The Scientiﬁc World Journal
control [10]. All these ﬁndings imply the pivotal role of
estrogens in the molecular events responsible for lactotrope
transformation and following prolactin-secreting adenoma
development.
Renin-angiotensin system (RAS) is an essential regulator
of the cardiovascular homeostasis and other fundamental
biological functions, including hormonal secretion and
cellular growth [11, 12]. Besides the circulating RAS, many
organs and tissues are capable of producing angiotensin
peptides [13–16]. All the components of RAS have been
identiﬁed also within pituitary gland, and the main bioactive
peptide of RAS, angiotensin II (ang II), has been proved to
be synthesized intrapituitary [17]. There are many reports
on the interaction between local tissue RAS and estrogens.
In the anterior lobe of rat pituitary, the expression of
angiotensin receptors (AT) ﬂuctuated during estrous cycle,
with the highest binding in diestrus and lowest binding in
estrus [18]. Moreover, the number of AT1 receptor subtype
and the activity of angiotensin-converting enzyme (ACE)
in anterior pituitary of ovariectomized (OVX) rats fell after
chronic treatment with E2 [19, 20]. Nevertheless, long-
term exposition of lactotropic cells to the synthetic estrogen,
diethylstilboestrol (DES), enhanced the AT1-dependent PRL
secretion and strengthened the intracellular calcium mobi-
lization and inositol phosphate generation in response to
ang II, suggesting the stimulatory eﬀects of estrogens on
the AT1-linked postreceptor mechanisms [21, 22]. Estrogens
were also shown to increase the plasma angiotensinogen
level and to stimulate the expression of angiotensinogen
mRNA in various tissues, including the pituitary gland [23].
Additionally, the release of ang II from hypothalamus has
been described to rise in response to estrogen [24]. Next,
a chronic exposition to DES led to the upregulation of the
AT2 receptor gene transcription and increase in the func-
tional AT2 receptor expression in anterior pituitary of rats
[25].
Increasing lines of evidence indicate the important role
of RAS in regulation of the cellular growth and angiogenesis
within pituitary gland. Ang II and its derivative, ang IV,
were found to exert the stimulatory eﬀects on the anterior
pituitary cell proliferation both in vitro and in vivo [26–
28]. These peptides stimulated also the activity of tyrosine
kinase (TK) in cells isolated from the estrogen-induced rat
pituitary tumors [29, 30]. In lactosomatotroph GH3 cell
culture, ang II, ang III, and ang IV were shown to aﬀect the
VEGF secretion [31]. Moreover, local or systemic RAS was
suggested to mediate the estrogen-induced vascular changes
in the anterior pituitary gland in rodents [52].
The goal of the present study was to investigate the
potential involvement of RAS in estrogen-induced cellular
proliferation and angiogenesis in anterior pituitary of rats.
We performed the experiments using a high estrogen-
responsive rat strain, Fisher 344 (F344). F344 is especially
susceptible to the estrogens’ growth promoting and tumor-
inducing eﬀects on the pituitary, as chronic treatment
of rat with E2 leads to the lactotrope proliferation and
following lactotropic tumor formation within a few months
[32].
2.MaterialandMethods
2.1. Animals. Four-week-old male Fisher 344 rats, weighing
∼60g each were used in the experiment. The animals
were kept in the controlled conditions of light/darkness
(12h/12h) and temperature (23 ± 2◦C) with standard
laboratory food and water available ad libitum.
All procedures were approved by The Local Animal Use
and Care Committee (no. Ł/BD/126).
2.2. Induction of Pituitary Cells Hyperplasia. The animals
underwent chronic oestrogen treatment using the silastic
capsules prepared from 5 mm long Silastic tubes of 1.57mm
inner diameter and 2.4mm outer diameter (Silastic Labora-
toryTubbing,DowCorning Corporation, USA).Thesetubes
were ﬁlled with a saturated solution of diethylstilboestrol
(DES; Stilboestrolum, Polfa, Poland) in 96% ethanol. After
evaporation of alcohol, the capsules, containing 8–10mg of
DES each, were sealed with silastic medical adhesive (Silastic
Medical Adhesive Silicone Type A, Dow Corning Corpora-
t i o n ,U S A ) ,p r o t e c t e df r o ml i g h ta n ds t o r e da t4 ◦C. Such
implants were estimated to release 18–45μg/day of DES [1]
andtoinducethemassivehyperplasiaofprolactincellsinthe
strain of rats used in the study.
To induce pituitary lactotropes hyperplasia, the animals
underwent the intraperitoneal (i.p.) ketamine (Ketanest,
Parke-Davis) anaesthesia (60mg/kg of body weight) follow-
ing the subcutaneous (s.c.) implantation of silastic capsules
in lumbar region of each rat.
2.3. Experimental Protocol and Preparation of Tissues. Three
days after capsules implantation, animals were divided into 5
groups (7 rats in each group) and started receiving examined
substances as follows:
(i) Group I (control group without capsules; DES−):
0.5mL 0.9% NaCl, i.p.;
(ii) Group II (control group with capsules; DES+):
0.5mL 0.9% NaCl, i.p.;
(iii) Group III: Losartan (Merck), 10mg/kg of body
weight, i.p.;
(iv) Group IV: PD123319 (PD123319 di(triﬂuoroace-
tate), Sigma), 1mg/kg of body weight, i.p.;
(v) Group V: Captoril (Sigma), 50mg/kg of body weight,
s.c.
Injections were made twice a day (every 12h) for the follow-
ing 6 days. Twelve hours after the last injections, all animals
were decapitated, pituitary glands were carefully isolated,
ﬁxed in 4% neutral buﬀered formalin and embedded in
paraﬃn. The 5μm thick sections of the pituitary glands were
mounted on normal glass slides for immunohistochemistry.
2.4. Immunohistochemistry
2.4.1. Cell Proliferation Study. The determination of the
proliferating cell nuclear antigen (PCNA) was applied as
an index of cell proliferation. Immunohistochemistry wasThe Scientiﬁc World Journal 3
performed using a PC 10 monoclonal antibody (Monoclonal
Mouse Anti-Rat Proliferating Cell Nuclear Antigen, Clone
PC 10, DakoCytomation). After wax removal, sections were
heatedincitratebuﬀer(pH6.0)inamicrowaveoven(700W,
10min) then chilled at room temperature and washed with
distilled water and in Tris/HCl buﬀer (pH 7.4). Sections
were then exposed to anti-PCNA PC 10 antibody for 10
minutes and washed again. The visualization of the reaction
was achieved using EnVision System-AP (DakoCytomation).
The protocol included incubation with Labelled Polymer
for 10min following washing procedure, incubation with
Fast Red solution for 25min, and subsequent washing
with distilled water. The sections were then stained with
hematoxylin for 45min.
2.4.2. VEGF Expression Study. VEGF expression in the
anterior pituitary gland cells and vessels was determined
using mouse monoclonal antibody IgG2α (VEGF (C-1),
Santa Cruz Biotechnology). After wax removal, sections
were heated in citrate buﬀer (pH 6.0) in a microwave oven
(700W, 5min) then chilled at room temperature, washed
with PBS and incubated with 3% hydrogen peroxide (H2O2
solution) to block the endogenous peroxidase. The sections
werethenincubatedwithanti-VEGF (C-1) immunoglobulin
at a dilution of 1:100 for 5min. To intensify the reaction,
StreptABComplez/HRP Duet, Mouse/Rabbit (DakoCytoma-
tion) kit was used. The protocol included incubation with
anti-mouse-IgG2α antibodies labeled with peroxidase (POD)
for 30min, washing with PBS, incubation with tetrachloride
3,3 -diaminobenzidine (DAB) solution for 4min (POD
substrate), and washing with running water. The sections
were then stained with hematoxylin for 60s.
2.4.3. Image Analysis. Digital images were acquired from
the light microscope (Olympus BX40, Japan) at ×200
magniﬁcation via CCD colour camera (CC20P; Videotronic
GmbH, Germany) and analyzed using a computer system
(MultiScanBase v.8.08; Computer Scanning System, Warsaw,
Poland).
The PCNA labeling index (LI) was assessed as a number
of PCNA-immunopositive nuclei per 1000 randomly scored
anterior pituitary cells in microscopic preparations at 600x
magniﬁcation. Minimum 4,000cells were counted in each
slice.
VEGF-immunopositive anterior pituitary cells were as-
sessed as a number of VEGF-immunopositive cells per
1000 randomly scored cells in microscopic preparations at
600x magniﬁcation. Moreover, the VEGF-immunopositive
cells were classiﬁed into one of three categories: the cells
with weak, medium, or strong VEGF immunoreactivity.
Minimum 4,000 cells were counted in each slice.
VEGF-immunopositive reaction in anterior pituitary ves-
selswas expressed as the mean number of VEGF-immu-
nopositive vessel sections per microscopic image, counted

















Figure 1: The inﬂuence of AT1 receptor antagonist losartan
(L), AT2 receptor antagonist PD123319 (PD), and ACE inhibitor
captopril (C) on diethylstilboestrol- (DES-) induced increase in
number of PCNA immunopositive cells in anterior pituitary of rats.
X ± SEM;
∗P < 0.05 versus C (DES−, control DES-untreated
group),
∗∗P<0.05 versus C (DES+, control DES-treated group),
LI: labeling index (the number of PCNA-immunopositive cells per
1000 randomly scattered cells of anterior pituitary).
2.5.StatisticalEvaluation. Theresultsareexpressedasmeans
± SEM. Comparisons of individual groups were evaluated by
analysisofvariance(ANOVA)followingLSD(leastdiﬀerence
test) Fisher test. Diﬀerences were signiﬁcant if P<0.05.
3. Results
The results of the quantitative analysis and the statistical
evaluation of these results are presented in Figures 1–5.
The 8-day treatment with DES resulted in a signiﬁcant
elevation in the proliferation index, expressed as a number
of the PCNA-immunopositive cells per 1000 randomly
scattered cells, in anterior pituitary of rats (Figures 1 and
2(b)). At the same time, the number of PCNA-positive cells
was signiﬁcantly decreased in anterior pituitary of animals
receiving the AT1 antagonist losartan, AT2 receptor antago-
nist PD123319 or ACE inhibitor captopril, comparing to the
DES-treated control group (Figures 1, 2(c), 2(d),a n d2(e)).
These data indicate the inhibitory eﬀects of RAS antagonists
on the estrogen-dependent pituitary cell proliferation.
Concomitantly, exposition of rats to DES led to the
increased VEGF immunoreactivity in anterior pituitary cells
and blood vessels (Figures 3, 4,a n d5(b)). Administration
of losartan, PD123319, or captopril resulted in a signiﬁcant
decrease in the number of VEGF-positive blood vessels.
(Figures 3, 5(c), 5(d) and 5(e)). The number of anterior
pituitary cells staining for VEGF diminished in animals
receiving only the AT1 antagonist and changed after co-
treatment with neither AT2 blocker nor ACE inhibitor
(Figures 4, 5(c), 5(d) and 5(e)).
4. Discussion
Pituitary gland is the source of various growth factors and
cytokines that regulate cellular growth in an autocrine and
paracrine manner [33]. Immunohistochemical studies have4 The Scientiﬁc World Journal
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Figure 2: Immunohistochemical staining for the proliferation cell nuclear antigen (PCNA) in anterior pituitary of rats; (a) control
diethylstilboestrol- (DES-) untreated group, (b) control DES-treated group, (c) DES and AT1 blocker (losartan) cotreated group, (d) DES
and AT2 blocker (PD12319) cotreated group, and (e) DES and angiotensin converting enzyme inhibitor (captopril) cotreated group. White

























































C (DES−) C (DES+) L PD C
Figure 3: The inﬂuence of AT1 receptor antagonist losartan (L),
AT2 receptor antagonist PD123319 (PD) and ACE inhibitor capto-
pril (C) on diethylstilboestrol- (DES-) induced increase in number
of vascular endothelial growth factor (VEGF) immunopositive cells
in anterior pituitary of rats. X ± SEM;
∗P < 0.05 versus C (DES−,
controlDES-untreatedgroup),
∗∗P<0.05versusC(DES+,control
DES-treated group). pale gray : weak VEGF immunoreactivity;
d a r kg r a y:m e d i u mV E G Fi m m u n o r e a c t i v i t y ; b l a c k:s t r o n gV E G F
immunoreactivity.
demonstrated that anterior pituitary cells are also able to
express the components of RAS [34, 35]. At the other hand,
angiotensin peptides have been shown to aﬀect the growth
of anterior pituitary cells. Ang II and ang IV increased
cellular proliferation in the primary culture rat lactotropes
[26]. These angiotensin peptides enhanced also BrdU incor-
poration in anterior pituitary of the ovariectomized female
rats in vivo [27]. Furthermore, RAS has been suggested to
mediate the estrogen-induced lactotropic cell proliferation



































































C (DES−) C (DES+) L PD C
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Figure 4: The inﬂuence of AT1 receptor antagonist losartan (L),
AT2 receptor antagonist PD123319 (PD) and ACE inhibitor capto-
pril (C) on diethylstilboestrol- (DES-) induced increase in number
of VEGF immunopositive blood vessels in anterior pituitary of rats.
X ± SEM;
∗P < 0.05 versus C (DES−, control DES-untreated
group),
∗∗P<0.05 versus C (DES+, control DES-treated group).
Inagreementwiththepreviousreports,chronicexposure
to DES signiﬁcantly increased the number of proliferating
cells in anterior pituitary of rats. This mitogenic eﬀect of
estrogen was abrogated by the ACE inhibitor, captopril.
Moreover, PCNA immunoreactivity was also signiﬁcantly
depressedinpituitaries ofanimalsreceivingtheAT1receptor
antagonist losartan or AT2 receptor antagonist PD123319,
comparing to the DES-treated control group. These ﬁndings
corroborate with the earlier results concerning the eﬀects
of sex steroids on PRL release. Suarez et al. revealed
that both the AT1 and AT2 receptor blockers inhibited






Figure 5: Immunohistochemical staining for vascular endothelial growth factor (VEGF) in anterior pituitary of rats; (a) control
diethylstilboestrol- (DES-) untreated group, (b) control DES-treated group, (c) DES and AT1 blocker (losartan) cotreated group, (d) DES
and AT2 blocker (PD12319) co-treated group, and (e) DES and angiotensin converting enzyme inhibitor (captopril) cotreated group. The
white arrows indicate the single-VEGF-positive pituitary cell, the black arrow indicates the VEGF immunopositive blood vessel, within the
black rectangular: the example isle of VEGF immunopositive cells in rat anterior pituitary.
the combined treatment with DES and progesterone [25].
Surprisingly, in previous in vivo study, neither losartan
nor PD123319 decreased the cellular proliferation in DES-
induced PRL-secreting tumor in rat, although it was inhib-
ited by angiotensin convertase inhibitor, enalaprilate [28].
This discrepancy may be possibly explained by the resistance
of prolactinoma cells to the growth-regulating factors. This
is highly probable, that following 12-week exposure to DES,
rat pituitary lactotropes have become autonomous, and thus
insensitive to the endogenous angiotensin peptides aﬀecting
the growth of unstimulated cells. In the present study,
we underwent animals to the only 8-day treatment with
DES, thus attempting to prevent the development of such
a pituitary cell autonomy. We believe that our experimental
modelhasledustoexaminetheestrogen-stimulated,butstill
susceptible to the growth factors anterior pituitary cells, at
the initial stages of the estrogen dependent tumorogenesis.
AT1 receptor is well established to be essential for the
mitogenic eﬀects of ang II in various tissues and organs [36–
41]. Moreover, blockade of AT1 signaling reduced tumor
growth, angiogenesis, and metastasis in the model of murine
sarcoma and ﬁbrosarcoma cells [42]. In contrast, AT2
receptor has been often demonstrated to counteract the
AT1-dependent proliferogenic actions [43, 44]. However,
ang-II-induced apoptosis of the rat cardiomyocytes was
connected with activation of both the AT2 and AT1 receptors
[45].Moreover,AT2causedconstitutive,ligand-independent
growth and did not antagonize AT1-mediated cardiomy-
ocytes hypertrophy [46]. Each of these receptors mediated
the stimulatory eﬀects of ang II on cellular proliferation and
apoptosis in renal glomerular epithelial tissue as well [47].
Such a cooperation of the AT1 and AT2 receptors has been
also demonstrated in our present study, as both receptors
appeared to mediate the estrogen-induced proliferation of
rat anterior pituitary cells.
Pituitary adenoma cells are able to produce the potent
angiogenic factor, VEGF, which is possibly involved in the
intratumoral blood vessel formation. VEGF was shown to
be present in various pituitary tumor cell lines, in primary
cultures of pituitary adenomas and in fragments from the
human pituitary adenomas obtained at surgery [8, 48]. The
production of this cytokine in lactosomatotroph GH3 cells
and in prolactinoma tumor cell preparations was stimulated
by estrogens [8, 49, 50]. Ochoa et al. observed also the
rapid and transient increase of VEGF in rat anterior pitu-
itary following E2 administration [49]. Estrogen treatment
augmented also the VEGF receptor 2 (ﬂk-1/KDR) expression
and induced neovascularisation as well as the growth and
enlargement of blood vessels in the rat pituitary [9, 51].
Similarl to the former data, we observed a signiﬁcant
elevation of the VEGF-immunopositive anterior pituitary
cells number and blood vessels density after 8-day expo-
sure of rats to DES. In the pituitaries of estrogen-treated
animals, the VEGF-positive cells were distributed in patches
surrounding the blood vessels and scattered through all
the glandular pituitary (Figure 5(b)). In contrast, only weak
staining signals with antibodies to VEGF were detected in
a separate, diﬀusely distributed pituitary cells of untreated
control animals (Figure 5(a)). Similar results were obtained
by Banerjee et al., who revealed a strong increase in both
the intracellular VEGF protein expression and in the VEGF-
positive blood vessel density in rat pituitary after 7 days of E2
exposure[9].Atthesametime,wenoticedasigniﬁcantfallin
the number of VEGF-immunostained cells as well as blood6 The Scientiﬁc World Journal
vessels in the pituitaries of rats receiving the speciﬁc AT1
receptor antagonist losartan. Treatment with ACE inhibitor
captopril or AT2 receptor antagonist PD123319 led to the
decline in VEGF-positive blood vessel density, whereas it did
not aﬀect the VEGF immunostaining in anterior pituitary
cells. These results are compatible with our earlier data,
showing that losartan is more eﬀective in inhibition of
the estrogen-induced pituitary vascular changes than AT2
blocker PD 123319 [52].
The inhibitory eﬀect of losartan suggests that AT1
receptors are involved in the control of VEGF expression,
in both pituitary cells and vessels. In contrast, the eﬀects of
PD123319, a selective AT2 receptor blocker, and of captopril,
an ACE inhibitor, on VEGF expression seem to be conﬁned
exclusivelytothebloodvessels.Recently,itwasshownthatin
human pituitary adenomas AT2 receptor immunopositivity
is absent in adenoma cells but it is very strong in blood
vessel walls [53]. If the same vascular localization of AT2
receptors concerns also the rat anterior pituitary, this could
explain the selective eﬀects of PD123319 on vascular VEGF.
The selective eﬀect of captopril on VEGF immunopositivity
in blood vessels is more diﬃcult to explain, since this agent
inhibitsangIIproduction,andthelatterisanagonistofboth
AT1 and AT2 receptors. However, it should be pointed that
inhibition of ang II synthesis leads to the enhanced synthesis
of smaller angiotensin peptides via alternative enzymatic
pathways [54]. Since the products of ang II degradation
have been shown to induce VEGF secretion by pituitary
cells, their overproduction possibly oﬀsets the decline of
VEGF production resulting from inhibited ang II synthesis.
Moreover, concomitant inﬂuences of ACE inhibitor on the
activity of various enzymes, diﬀerent from ACE, should be
taken into consideration. ACE inhibitors are established to
induce kininase II, increasing thereby the tissue bradykinin
concentration and aﬀecting angiogenesis via endothelial NO
release. Thanks to the presence the thiol radical, captopril
is also able to exert the direct inﬂuence on vascular growth
[55, 56].
Regardless the direct proangiogenic activities of angi-
otensin, the indirect eﬀects of RAS and its inhibitors on
the anterior pituitary angiogenesis should not be excluded.
The full-length PRL molecule has been shown to possess
angiogeniceﬀectinaninvivoassaysusingthechickchorioal-
lantoicmembrane(CAM)[57].Ontheotherhand,estrogens
belong to the potent stimuli of PRL secretion, whereas both
ACE inhibitors and angiotensin receptor antagonists have
been proved to suppress the DES-induced release of PRL
[28]. In this context we can not exclude that inhibition
of PRL release following the administration of captopril,
losartan, or PD123319 may response, at least in part, for the
decrease in number of VEGF-positive vessels in rat anterior
pituitary. The identiﬁcation of mechanisms engaged in the
RAS-dependent regulation of angiogenesis in the pituitary
gland needs further studies.
The involvement of RAS in regulation of the VEGF-de-
pendent angiogenesis has already been reported with respect
to various tissues [58–62].Thisisalsoworthmentioningthat
b o t ht h eA T 1a n dA T 2r e c e p t o rh a sb e e nf o u n dt op a rt i c i p a t e
in proangiogenic eﬀects of angiotensins. The AT1 receptor
subtype was implicated in the regulation of angiogenesis
during skeletal muscle regeneration, the increase of vessel
density in cremaster muscle of rats, the induction of
VEGF receptor expression in bovine retinal microcapillary
endothelial cells, and the VEGF-dependent angiogenesis in
the Matrigel model in mice [63–66]. At the other hand,
a higher VEGF expression in the retina of experimental
diabetic rats and ang-II-treated rats was partially determined
by AT2 receptor activation [67]. The AT2 receptor blockade
resulted in an important decrease of the VEGF and its recep-
tor KDR expression in kidney of ang-II-infused rats [68].
Furthermore, the AT2 receptor blockade using PD123319
in animal in vivo models of ﬁbrosarcoma and LL/2 cells
carcinoma delayed tumorigenesis by inhibiting malignant
cellproliferationandangiogenesisaswell[69].Similareﬀects
were obtained with respect to the anterior pituitary cells. In
earlier in vitro study, losartan and PD123319 abrogated the
stimulatory inﬂuence of ang II on VEGF secretion in GH3
cell culture [31]. Furthermore, the antagonists of both the
AT1 and AT2 receptors were also demonstrated to prevent
the DES-induced enlargement of blood vessels in anterior
pituitary in rodents [52]. Taken together, the present and
the previous results imply, that RAS mediates estrogen-
induced vascular growth in anterior pituitary, and this
processinvolvestheinductionandsecretionofVEGFviaAT1
and AT2 receptors.
Summing up, our results suggest the involvement of RAS
in DES-induced cellular proliferation and VEGF expression
in anterior pituitary of rat. Both AT1 and AT2 receptors
appeartomediatetheobservedmitogenicandproangiogenic
eﬀects of estrogens. Since cellular proliferation and blood
vessel formation are indispensable for the tumor develop-
ment, our study may suggest the participation of RAS in
pathogenesis of estrogen-induced PRL-secreting adenoma.
Further studies are necessary to extend the reported above
properties of RAS antagonists of the to human lactotropic
cells.
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